Randomized phase II clinical study on preventive effects of GPS, healthy food on the incidence of infection cases in stomach and colon cancer patients before and after the abdominal surgery
|Health condition(s) or Problem(s) studied
|stomach and colon cancer patients
|Date of first enrollment
|Target sample size
|Countries of recruitment
|GPS group 250mg of GPS (a cupsel contain 125mg of GPS) are orally taken continuously for 3 days before operation and for 27days after opperation.
|incidence of Surgical Site Infection
Key inclusion & exclusion criteria
|Male and Female
|1. Sevier compromised patient(more than PS3) 2. Patient of SHOWKAKAN KYOUSAKU or breading 3. SHINKOUSEI infectious patient 4. Urgent operation patient 5. ZOUKIFUZEN patient 6. Uncontrollable patients together with diabetes mellitus and treated with insulin 7. Suspected cases allergic to yeasts 8. Patient who has been treated with chemotherapy 9. Other patients who are considered to be ruled out by the doctor concerned
|Research institute of cancer chemotherapy
|Source(s) of Monetary Support
|Nippon Biothera Co., Ltd.
|Tsunesuke Kajimoto, Ph.D.
|2-3-26 Kudanminami,Chiyoda-ku,Tokyo 102-00074,Japan Japan
|Nippon Biothera Co., Ltd. Healthcare Division
|Professor Kenji Ogawa
|2-1-10 Nishioku,akawa-ku,Tokyo 1160-8567,Japan Japan
|Tokyo wemen college of medicine, East clinical center Surgicaldepartment